Next Generation Vaccines for Multi-Resistant Bacteria


Discover and develop safe and effective vaccines to overcome infectious challenges threatening global public health


A world free of suffering from infectious diseases

Proxi Biotech's BACTOVAC platform technology offers superior vaccines to overcome the challenge of resistant bacteria

Antimicrobial resistance (AMR) is one of the world's most pressing medical problems. More than 700,000 people die each year from infections resistant to antibiotics. By 2050, such infections are expected to kill 10,000,000 people.

Proxi Biotech, an early stage spin-off from the Serum Institute of Denmark, has developed the BACTOVAC platform technology for detoxification of bacterial toxins. BACTOVAC overcomes main barriers of traditional vaccine developing technologies that allows new, highly needed vaccine to enter market and fight multi-resistant bacteria


Contact information

Proxi Biotech ApS

Nørre Allé 41

2200 Copenhagen


Tel:       +45 2255 2202

Email:   rj@proxibiotech.com

Copyright 2019 Proxi Biotech All Rights Reserved